Key factors in the rising cost of new drug discovery and development

被引:313
作者
Dickson, M [1 ]
Gagnon, JP
机构
[1] Univ S Carolina, Coll Pharm, Columbia, SC 29208 USA
[2] Aventis Pharmaceut, Bridgewater, NJ 08807 USA
关键词
D O I
10.1038/nrd1382
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The public desire for new therapies, their increasing cost and the increased role of government as a payer for innovative new drugs all converge on the issue of the rapidly rising cost of new drug development-now thought to be greater than US $800 million-and highlight the necessity for an efficient use of resources. With this in mind, here we review studies on the cost of developing new drugs and consider how this cost has, and could be, affected by the changing environment for pharmaceutical research and development.
引用
收藏
页码:417 / 429
页数:13
相关论文
共 52 条
[1]  
[Anonymous], 2004, HEART DIS STROK STAT
[2]  
*CTR MED MED SERV, 2004, HOSP OUTP PROSP PAYM
[3]   Risks in new drug development: Approval success rates for investigational drugs [J].
DiMasi, JA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (05) :297-307
[4]   The price of innovation: new estimates of drug development costs [J].
DiMasi, JA ;
Hansen, RW ;
Grabowski, HG .
JOURNAL OF HEALTH ECONOMICS, 2003, 22 (02) :151-185
[5]   SUCCESS RATES FOR NEW DRUGS ENTERING CLINICAL-TESTING IN THE UNITED-STATES [J].
DIMASI, JA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (01) :1-14
[6]   The value of improving the productivity of the drug development process - Faster times and better decisions [J].
DiMasi, JA .
PHARMACOECONOMICS, 2002, 20 (Suppl 3) :1-10
[7]   COST OF INNOVATION IN THE PHARMACEUTICAL-INDUSTRY [J].
DIMASI, JA ;
HANSEN, RW ;
GRABOWSKI, HG ;
LASAGNA, L .
JOURNAL OF HEALTH ECONOMICS, 1991, 10 (02) :107-142
[8]   New drug development in the United States from 1963 to 1999 [J].
DiMasi, JA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (05) :286-296
[9]   NEW DRUG DEVELOPMENT IN THE UNITED-STATES FROM 1963 TO 1990 [J].
DIMASI, JA ;
BRYANT, NR ;
LASAGNA, L .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 50 (05) :471-486
[10]  
DIMASI JA, 1995, DRUG INF J, V29, P375